Notably, FGF21 analogs have reduced insulin resistance or decreased liver fat in clinical trials16,26; however, administration of retatrutide at higher doses significantly reduced circulating FGF21 levels, suggesting that retatrutide efficacy in MASLD is unlikely to be attributable to increased FGF21 levels. The gene discussed is FGF21; the disease is metabolic dysfunction-associated steatotic liver disease.